Celldex ( Celldex )


Celldex's picture

About Celldex

Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates.

Celldex press release, blog etc

06/02/2018 - 07:08 Celldex Presents Promising Data from Phase 1/2 Study of Varlilumab and Opdivo at 2018 ASCO Annual Meeting
05/16/2018 - 13:47 Celldex Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
04/20/2018 - 05:07 Data from Multiple Celldex Programs Presented at American Association for Cancer Research (AACR) Annual Meeting 2018
04/16/2018 - 02:38 Celldex's METRIC Study in Metastatic Triple-negative Breast Cancer Does Not Meet Primary Endpoint
03/07/2018 - 16:40 Celldex Provides Corporate Update and Reports Full Year 2017 Results
11/30/2017 - 07:57 Celldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors
11/17/2017 - 08:52 Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma
10/03/2017 - 06:58 Celldex Therapeutics Appoints Margo Heath-Chiozzi, M.D., as Senior Vice President, Regulatory Affairs
09/12/2017 - 12:15 Celldex Announces Departure of Chief Medical Officer
08/23/2017 - 08:40 Celldex Announces Completion of Enrollment in Phase 2b Study of Glembatumumab Vedotin in Triple Negative Breast Cancer
06/16/2017 - 11:08 Celldex Therapeutics Announces Additions to the Board of Directors and Senior Management Team
06/05/2017 - 11:16 Celldex Presents Promising Overall Survival Data from Phase 2 Study of Single-agent Glembatumumab Vedotin in Patients with Checkpoint-Refractory Metastatic Melanoma
06/05/2017 - 10:14 Celldex Therapeutics Presents Phase 1 Study of Varlilumab and Opdivo at 2017 ASCO Annual Meeting
06/02/2017 - 12:21 Celldex Therapeutics to Present Clinical Results at 2017 ASCO Annual Meeting
03/14/2017 - 14:56 Celldex Provides Corporate Update and Reports Full Year 2016 Results
02/13/2017 - 14:13 Celldex Therapeutics Announces Upcoming Investor Presentations and 2016 Year-End Call
12/14/2016 - 17:12 Celldex Therapeutics Announces Appointment to Board of Directors
12/05/2016 - 15:09 Theresa LaVallee, Ph.D., Joins Celldex Therapeutics' Senior Management Team